Development of an assay to screen for inhibitors of tau phosphorylation by cdk5

被引:14
作者
Ahn, JS
Musacchio, A
Mapelli, M
Ni, J
Scinto, L
Stein, R
Kosik, KS
Yeh, LA
机构
[1] Harvard Univ, Sch Med, Brigham & Womens Hosp, Ctr Neurol Dis,Lab Drug Discovery Neurodegenerat, Boston, MA USA
[2] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Neurol,Lab Higher Cort Funct, Boston, MA USA
[3] European Inst Oncol, Dept Expt Oncol, Milan, Italy
关键词
HTS; cdk5; tau phosphorylation; Alzheimer's disease;
D O I
10.1177/1087057103260594
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A high-throughput assay for tau phosphorylation by cdk5/p25 is described. Full-length recombinant tau was used as a substrate in the presence of saturating adenosine triphosphate (ATP). Using PHF-1, an antibody directed specifically against 2 tau phosphorylation epitopes (serine 396 and serine 404), an enzyme-linked immunosorbent assay (ELISA)-based colorimetric assay was formatted in 384-well plates. The assay was validated by measuring kinetic parameters for cdk5/p25 catalysis and known inhibitors. Rate constants for the site-specific phosphorylations at the PHF-1 epitopes were determined and suggested preferential phosphorylation at these sites. The performance of this assay in a high-throughput format was demonstrated and used to identify inhibitors of tau phosphorylation at specific epitopes phosphorylated by cdk5/p25.
引用
收藏
页码:122 / 131
页数:10
相关论文
共 40 条
[1]   TAU-PROTEIN KINASE-II IS INVOLVED IN THE REGULATION OF THE NORMAL PHOSPHORYLATION STATE OF TAU-PROTEIN [J].
ARIOKA, M ;
TSUKAMOTO, M ;
ISHIGURO, K ;
KATO, R ;
SATO, K ;
IMAHORI, K ;
UCHIDA, T .
JOURNAL OF NEUROCHEMISTRY, 1993, 60 (02) :461-468
[2]   Specific tau phosphorylation sites correlate with severity of neuronal cytopathology in Alzheimer's disease [J].
Augustinack, JC ;
Schneider, A ;
Mandelkow, EM ;
Hyman, BT .
ACTA NEUROPATHOLOGICA, 2002, 103 (01) :26-35
[3]   DISTRIBUTION OF THE PHOSPHORYLATED MICROTUBULE-ASSOCIATED PROTEIN-TAU IN DEVELOPING CORTICAL-NEURONS [J].
BRION, JP ;
OCTAVE, JN ;
COUCK, AM .
NEUROSCIENCE, 1994, 63 (03) :895-909
[4]  
CORREAS I, 1992, J BIOL CHEM, V267, P15721
[5]   A decade of CDK5 [J].
Dhavan, R ;
Tsai, LH .
NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2001, 2 (10) :749-759
[6]   MITOGEN ACTIVATED PROTEIN (MAP) KINASE TRANSFORMS TAU-PROTEIN INTO AN ALZHEIMER-LIKE STATE [J].
DREWES, G ;
LICHTENBERGKRAAG, B ;
DORING, F ;
MANDELKOW, EM ;
BIERNAT, J ;
GORIS, J ;
DOREE, M ;
MANDELKOW, E .
EMBO JOURNAL, 1992, 11 (06) :2131-2138
[7]   Tau phosphorylation at serine 396 and serine 404 by human recombinant tau protein kinase II inhibits tau's ability to promote microtubule assembly [J].
Evans, DB ;
Rank, KB ;
Bhattacharya, K ;
Thomsen, DR ;
Gurney, ME ;
Sharma, SK .
JOURNAL OF BIOLOGICAL CHEMISTRY, 2000, 275 (32) :24977-24983
[8]  
Fischer P M, 2001, Curr Opin Drug Discov Devel, V4, P623
[9]   CDK inhibition and cancer therapy [J].
Garrett, MD ;
Fattaey, A .
CURRENT OPINION IN GENETICS & DEVELOPMENT, 1999, 9 (01) :104-111
[10]  
Gray N, 1999, CURR MED CHEM, V6, P859